Extension Study of ABP-671 in Participants With Gout

Summary

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

Timeline

Start

2024-04-22

Primary completion

2024-09-05

Completion

2024-09-05

Drugs

Indications